Program
CHO cell
Also written as “Recombinant new coronavirus vaccine (CHO cell) group”, “Recombinant Zoster Vaccine (CHO Cell)” and “Recombinant two-component COVID-19 vaccine (CHO cell)”.
Its studies are mostly in COVID-19 · Herpes Zoster · Coronavirus Infections · Kidney Failure, Chronic, led by 7 companies.
Drug pageCHO cell: every studyMany companies study it; this page follows only the 29 they lead. All 35 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Zhifei Biological Productsits history only | 121 open or running | phase 4since Mar 28, 2022 | Jun 16, 2020 | none ahead |
| Jiangsu Rec-Biotechnologyits history only | 50 open or running | phase 3since May 30, 2022 | Mar 19, 2021 | none ahead |
| MAXVAX Biotechnology Limited Liabilityits history only | 54 open or running | phase 3since Jun 2, 2024 | Jun 2, 2024 | Dec 31, 2027phase 3 · NCT07293065 |
| 3SBioits history only | 20 open or running | phase 3since Jan 13, 2022 | May 10, 2019 | none ahead |
| Guangzhou Patronus Biotech | 20 open or running | phase 3since Dec 23, 2022 | Dec 23, 2022 | none ahead |
| Sinopharmits history only | 20 open or running | phase 2since Apr 24, 2021 | Apr 24, 2021 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 2since Oct 19, 2026 | Oct 19, 2026 | Jul 31, 2027phase 2 · NCT07892989 |
Also a collaborator on its studies: Yantai Patronus Biotech and Iqvia Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Guangzhou Patronus Biotech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2022First studies: 2 phase 3 studies in COVID-19First studyNCT05664932, NCT05683600
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Guangzhou Patronus Biotech leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05683600COVID-19 · China | 3 | Terminated | Jul 12, 2023 | 3,000 |
| NCT05664932COVID-19 · China | 3 | UNKNOWN | Jan 18, 2023 | 1,200 |
How it is read
Names in the registry
- “Recombinant new coronavirus vaccine (CHO cell) group”, 5 entries
- “Recombinant Zoster Vaccine (CHO Cell)”, 3 entries
- “Recombinant two-component COVID-19 vaccine (CHO cell)”, 3 entries
- “Recombinant RSV Vaccine (CHO Cell)”, 2 entries
- “Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)”, 2 entries
Conditions, from the studies’ own filings
- COVID-19, 16 studies
- Herpes Zoster, 5 studies
- Coronavirus Infections, 4 studies
- Kidney Failure, Chronic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.